• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

掩味氟氯西林粉末 第1部分:采用混合设计方法优化制备工艺

Taste-Masked Flucloxacillin Powder Part 1: Optimisation of Fabrication Process Using a Mixture Design Approach.

作者信息

Yoo Okhee, Salman Sam, von Ungern-Sternberg Britta S, Lim Lee Yong

机构信息

Pharmacy, School of Allied Health, University of Western Australia, Perth, WA 6009, Australia.

Clinical Pharmacology and Toxicology Unit, PathWest Laboratory Medicine, Perth, WA 6009, Australia.

出版信息

Pharmaceuticals (Basel). 2023 Aug 17;16(8):1171. doi: 10.3390/ph16081171.

DOI:10.3390/ph16081171
PMID:37631086
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10458362/
Abstract

It is extremely challenging to formulate age-appropriate flucloxacillin medicines for young children, because flucloxacillin sodium (FS) has a lingering, highly bitter taste, dissolves quickly in saliva, and requires multiple daily dosing at relatively large doses for treating skin infections. In this paper, we describe a promising taste-masked flucloxacillin ternary microparticle (FTM) formulation comprising FS, Eudragit EPO (EE), and palmitic acid (PA). To preserve the stability of the thermolabile and readily hydrolysed flucloxacillin, the fabrication process employed a non-aqueous solvent evaporation method at ambient temperature. Optimisation of the fabrication method using a mixture design approach resulted in a robust technique that generated stable and reproducible FTM products. The optimised method utilised only a single solvent evaporation step and minimal amounts of ICH class III solvents. It involved mixing two solution phases-FS dissolved in ethanol:acetone (1:4 /), and a combination of EE and PA dissolved in 100% ethanol-to give a ternary FS:EE:PA system in ethanol: acetone (3:1 /). Solvent evaporation yielded the FTMs containing an equimolar ratio of FS:EE:PA (1:0.8:0.6 /). The fabrication process, after optimisation, demonstrated robustness, reproducibility, and potential scalability.

摘要

为幼儿配制适合其年龄的氟氯西林药物极具挑战性,因为氟氯西林钠(FS)有持久的强烈苦味,在唾液中溶解迅速,且治疗皮肤感染时需要每日多次服用相对大剂量的药物。在本文中,我们描述了一种有前景的掩味氟氯西林三元微粒(FTM)制剂,其由FS、丙烯酸树脂EPO(EE)和棕榈酸(PA)组成。为保持热不稳定且易水解的氟氯西林的稳定性,制备过程采用了常温下的非水溶剂蒸发法。使用混合设计方法对制备方法进行优化,得到了一种可靠的技术,可生产出稳定且可重复的FTM产品。优化后的方法仅使用单一溶剂蒸发步骤和极少量的国际协调会议(ICH)III类溶剂。该方法包括将两个溶液相混合——FS溶解于乙醇:丙酮(1:4 v/v)中,以及EE和PA的混合物溶解于100%乙醇中——从而在乙醇:丙酮(3:1 v/v)中形成三元FS:EE:PA体系。溶剂蒸发得到了含有等摩尔比FS:EE:PA(1:0.8:0.6 w/w)的FTM。优化后的制备过程展现出了稳健性、可重复性和潜在的可扩展性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3cd8/10458362/0661afc7ff56/pharmaceuticals-16-01171-g016.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3cd8/10458362/a00f5fd7283e/pharmaceuticals-16-01171-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3cd8/10458362/12c9dea38843/pharmaceuticals-16-01171-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3cd8/10458362/5f1341b2bc8f/pharmaceuticals-16-01171-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3cd8/10458362/57da86964665/pharmaceuticals-16-01171-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3cd8/10458362/fceeb6868d5d/pharmaceuticals-16-01171-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3cd8/10458362/430c5a953eb5/pharmaceuticals-16-01171-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3cd8/10458362/c9423e9a9a61/pharmaceuticals-16-01171-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3cd8/10458362/8ccd35ca0807/pharmaceuticals-16-01171-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3cd8/10458362/8256dedfe90f/pharmaceuticals-16-01171-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3cd8/10458362/c62f10a9ad49/pharmaceuticals-16-01171-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3cd8/10458362/92c496b661cd/pharmaceuticals-16-01171-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3cd8/10458362/f9f8e2eca2ae/pharmaceuticals-16-01171-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3cd8/10458362/07d22aa0a435/pharmaceuticals-16-01171-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3cd8/10458362/27d09084fae0/pharmaceuticals-16-01171-g014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3cd8/10458362/3959bd04de2b/pharmaceuticals-16-01171-g015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3cd8/10458362/0661afc7ff56/pharmaceuticals-16-01171-g016.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3cd8/10458362/a00f5fd7283e/pharmaceuticals-16-01171-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3cd8/10458362/12c9dea38843/pharmaceuticals-16-01171-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3cd8/10458362/5f1341b2bc8f/pharmaceuticals-16-01171-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3cd8/10458362/57da86964665/pharmaceuticals-16-01171-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3cd8/10458362/fceeb6868d5d/pharmaceuticals-16-01171-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3cd8/10458362/430c5a953eb5/pharmaceuticals-16-01171-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3cd8/10458362/c9423e9a9a61/pharmaceuticals-16-01171-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3cd8/10458362/8ccd35ca0807/pharmaceuticals-16-01171-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3cd8/10458362/8256dedfe90f/pharmaceuticals-16-01171-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3cd8/10458362/c62f10a9ad49/pharmaceuticals-16-01171-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3cd8/10458362/92c496b661cd/pharmaceuticals-16-01171-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3cd8/10458362/f9f8e2eca2ae/pharmaceuticals-16-01171-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3cd8/10458362/07d22aa0a435/pharmaceuticals-16-01171-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3cd8/10458362/27d09084fae0/pharmaceuticals-16-01171-g014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3cd8/10458362/3959bd04de2b/pharmaceuticals-16-01171-g015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3cd8/10458362/0661afc7ff56/pharmaceuticals-16-01171-g016.jpg

相似文献

1
Taste-Masked Flucloxacillin Powder Part 1: Optimisation of Fabrication Process Using a Mixture Design Approach.掩味氟氯西林粉末 第1部分:采用混合设计方法优化制备工艺
Pharmaceuticals (Basel). 2023 Aug 17;16(8):1171. doi: 10.3390/ph16081171.
2
Taste-Masked Flucloxacillin Powder Part 2: Formulation Optimisation Using the Mixture Design Approach and Storage Stability.掩味氟氯西林粉末 第2部分:采用混合设计方法的制剂优化及储存稳定性
Pharmaceuticals (Basel). 2023 Aug 18;16(8):1179. doi: 10.3390/ph16081179.
3
Novel taste-masked orally disintegrating tablets for a highly soluble drug with an extremely bitter taste: design rationale and evaluation.新型掩味口腔崩解片用于具有极苦味道的高水溶性药物:设计原理与评价。
Drug Dev Ind Pharm. 2013 Sep;39(9):1364-71. doi: 10.3109/03639045.2012.718784. Epub 2012 Sep 20.
4
Preparation and evaluation of tablets rapidly disintegrating in saliva containing bitter-taste-masked granules by the compression method.采用压制法制备含掩味颗粒且能在唾液中快速崩解的片剂并进行评价。
Chem Pharm Bull (Tokyo). 1999 Oct;47(10):1451-4. doi: 10.1248/cpb.47.1451.
5
Taste masking of enalapril maleate by microencapsulation in Eudragit EPO microparticles.马来酸依那普利的包衣微囊化掩味研究。
Pharmazie. 2020 Mar 20;75(2):61-69. doi: 10.1691/ph.2020.9123.
6
Optimising poly(lactic-co-glycolic acid) microparticle fabrication using a Taguchi orthogonal array design-of-experiment approach.采用 Taguchi 正交数组实验设计方法优化聚(乳酸-共-乙醇酸)微球的制备。
PLoS One. 2019 Sep 26;14(9):e0222858. doi: 10.1371/journal.pone.0222858. eCollection 2019.
7
A new strategy for taste masking of azithromycin antibiotic: development, characterization, and evaluation of azithromycin titanium nanohybrid for masking of bitter taste using physisorption and panel testing studies.阿奇霉素抗生素掩味的新策略:阿奇霉素钛纳米杂化物的开发、表征及评价——利用物理吸附和感官测试研究来掩盖苦味
Drug Des Devel Ther. 2018 Nov 8;12:3855-3866. doi: 10.2147/DDDT.S183534. eCollection 2018.
8
Development and evaluation of orally disintegrating tablets comprising taste-masked mirtazapine granules.包含掩味米氮平颗粒的口腔崩解片的研制与评价。
Pharm Dev Technol. 2018 Jun;23(5):488-495. doi: 10.1080/10837450.2017.1315670. Epub 2017 Apr 13.
9
Formulation and biopharmaceutical evaluation of bitter taste masking microparticles containing azithromycin loaded in dispersible tablets.载于分散片的阿奇霉素微丸的包衣和生物药剂学评价。
Eur J Pharm Biopharm. 2018 May;126:187-200. doi: 10.1016/j.ejpb.2017.03.017. Epub 2017 Mar 27.
10
Kinetics of solvent extraction/evaporation process for PLGA microparticle fabrication.用于聚乳酸-羟基乙酸共聚物(PLGA)微粒制备的溶剂萃取/蒸发过程动力学
Int J Pharm. 2008 Nov 19;364(1):45-53. doi: 10.1016/j.ijpharm.2008.08.015. Epub 2008 Aug 22.

引用本文的文献

1
Assembled pH-Responsive Gastric Drug Delivery Systems Based on 3D-Printed Shells.基于3D打印外壳的组装式pH响应型胃内给药系统
Pharmaceutics. 2024 May 27;16(6):717. doi: 10.3390/pharmaceutics16060717.
2
Taste-Masked Flucloxacillin Powder Part 2: Formulation Optimisation Using the Mixture Design Approach and Storage Stability.掩味氟氯西林粉末 第2部分:采用混合设计方法的制剂优化及储存稳定性
Pharmaceuticals (Basel). 2023 Aug 18;16(8):1179. doi: 10.3390/ph16081179.

本文引用的文献

1
PubChem in 2021: new data content and improved web interfaces.PubChem 在 2021 年:新增数据内容和改进的网络界面。
Nucleic Acids Res. 2021 Jan 8;49(D1):D1388-D1395. doi: 10.1093/nar/gkaa971.
2
Effect of Trapped Solvent on the Interface between PS--PMMA Thin Films and P(S--MMA) Brush Layers.截留溶剂对聚苯乙烯-聚甲基丙烯酸甲酯薄膜与聚(苯乙烯-甲基丙烯酸甲酯)刷层之间界面的影响。
ACS Appl Mater Interfaces. 2020 Feb 12;12(6):7777-7787. doi: 10.1021/acsami.9b20801. Epub 2020 Jan 30.
3
Taste masking of propranolol hydrochloride by microbeads of EUDRAGIT® E PO obtained with prilling technique for paediatric oral administration.
采用制粒技术将 EUDRAGIT® E PO 微球用于盐酸普萘洛尔的掩味,便于儿科口服。
Int J Pharm. 2020 Jan 25;574:118922. doi: 10.1016/j.ijpharm.2019.118922. Epub 2019 Dec 10.
4
Characterizing the pH-Dependent Release Kinetics of Food-Grade Spray Drying Encapsulated Iron Microcapsules for Food Fortification.表征用于食品强化的食品级喷雾干燥包封铁微胶囊的pH依赖性释放动力学
Food Bioproc Tech. 2018;11(2):435-446. doi: 10.1007/s11947-017-2022-0. Epub 2017 Nov 15.
5
Flucloxacillin: A Review of Characteristics, Properties and Analytical Methods.氟氯西林:特性、性质和分析方法综述。
Crit Rev Anal Chem. 2019;49(1):67-77. doi: 10.1080/10408347.2018.1468728. Epub 2018 May 30.
6
Structure Formation in Soft-Matter Solutions Induced by Solvent Evaporation.溶剂蒸发诱导的软物质溶液中的结构形成。
Adv Mater. 2017 Dec;29(45). doi: 10.1002/adma.201703769. Epub 2017 Oct 23.
7
A comprehensive review on polyelectrolyte complexes.聚电解质复合物综述
Drug Discov Today. 2017 Nov;22(11):1697-1706. doi: 10.1016/j.drudis.2017.06.008. Epub 2017 Jul 3.
8
A mixed methods study of the administration of flucloxacillin oral liquid; identifying strategies to overcome administration issues of medicines with poor palatability.一项关于氟氯西林口服液给药的混合方法研究;确定克服口感不佳药物给药问题的策略。
Int J Pharm Pract. 2017 Oct;25(5):326-334. doi: 10.1111/ijpp.12308. Epub 2016 Sep 16.
9
Effect of formulation variables on oral grittiness and preferences of multiparticulate formulations in adult volunteers.制剂变量对成年志愿者口服多颗粒制剂的砂质感及偏好的影响。
Eur J Pharm Sci. 2016 Sep 20;92:156-62. doi: 10.1016/j.ejps.2016.07.006. Epub 2016 Jul 9.
10
Development and Evaluation of Taste Masked Granular Formulation of Satranidazole by Melt Granulation Technique.通过熔融制粒技术开发和评估沙硝唑掩味颗粒制剂
J Pharm (Cairo). 2014;2014:789676. doi: 10.1155/2014/789676. Epub 2014 Feb 12.